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Background: Abnormal glucose tolerance is a frequent co-morbidity in cystic fibrosis patients (CF), and is associated with a worse
prognosis. The objectives are to investigate (a) the relative contribution of insulinopenia and insulin resistance (IR) for glucose tolerance and
(b) the association between various glucose parameters and CF clinical status.
Methods: Oral glucose tolerance tests were performed in 114 consecutive CF patients not known to be diabetic as well as 14 controls similar
for age and BMI.
Results: Abnormal glucose tolerance was found in 40% of patients with CF: 28% had impaired glucose tolerance (IGT) and 12% had new
cystic fibrosis related diabetes (CFRD). Compared to control subjects, all CF patients were characterized by an increased glucose excursion
(AUC). While reduced early insulin release characterised CF, IGT and CFRD patients also present IR thus both mechanisms significantly
contribute to glucose tolerance abnormalities. Increased glucose AUC and reduced early insulin release but not glucose tolerance categories
were associated with a reduced pulmonary function (FEV1).
Conclusion: In CF, early insulin secretion defect but also IR contribute to glucose intolerance. Early in the course of the disease, increased
glucose AUC and reduced early insulin secretion are more closely associated with a worse clinical status than conventional glucose tolerance
categories.
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Impaired glucose tolerance (IGT) and cystic fibrosis
related diabetes (CFRD), are the first co-morbidity in cystic
fibrosis (CF) and their prevalence is increasing along with the
improved survival of CF patients [1]. CFRD is an important
marker of a worsening prognosis with a higher mortality rate
[1–3]. Several studies have reported a decline in nutritional
and pulmonary status 2 to 4 years before the diagnosis of
CFRD [4]. Based on the natural history of the disease, this
could be due to the impaired glucose tolerance whiched by Elsevier B.V. All rights reserved.
1 Index for insulin sensitivity: 0.156−0.0000459×Ins120−0.0003211×
Ins0−0.00541×Glucose120.
2 Index for early insulin release: 1283+1.829×Ins30−138.7×Glucose30+
3.772×Ins0.
3 Index for late insulin release: 287+0.4164×Ins30−26.07×Glucose30+
0.9226×Ins0.
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pathophysiology of glucose intolerance in CF is poorly
understood. Indeed, insulin secretion deficiency is believed
to be the primary cause of CFRD, however, the contribution
of insulin resistance remains controversial [3,5,6]. Moreover,
the relative contribution of insulin secretion defect and
insulin resistance to both the glucose intolerance and the
clinical status is unclear.
We hypothesised that both mechanisms, impaired insulin
secretion and reduced insulin sensitivity, are involved in the
development of glucose intolerance and that they would be
associated with the deterioration of the clinical status in CF
subjects. Therefore, the purpose of this study was (a) to
investigate the relative contribution of insulin secretion
defect and insulin resistance in the development of glucose
intolerance and (b) to identify in a large cohort of CF patients
without known CFRD factors which are the most closely
associated with clinical deterioration: glucose intolerance,
glucose excursion, insulin secretion defect and/or insulin
resistance.
2. Subjects and methods
2.1. Subjects
As part of an ongoing systematic screening program to
detect CFRD, 114 consecutive CF patients were included
in the study between February 2004 and October 2005.
The protocol was approved by the Institutional Review
Board of Centre Hospitalier de l'Université de Montréal
and all subjects signed a consent form. Male or female CF
patients over 18 years of age were included in the study.
Exclusion criteria were presence in the previous month of
(I) exacerbation defined by: change in sputum production
(volume, colour, consistency), new or increased haemop-
tysis, increased cough, increased dyspnea, malaise fatigue
or lethargy, fever >38 °C, anorexia, sinus pain, a 10%
decrease in FEV1 as shown by previously recorded value
(each 3 months), intravenous antibiotic treatment and
changes in chest sounds; (II) medication that interferes
with glucose metabolism (i.e. oral or IV steroids, growth
hormone, megace, etc.); (III) known diabetes; (IV) fasting
plasma glucose over 7.0 mmol/L or (V) pregnancy.
Exacerbation was determined by a trained CF-pneumolo-
gist blinded to glucose values. Fourteen subjects with a
normal glucose tolerance and without CF corresponding
for sex, age and body mass index (BMI) were recruited as
a control group.
2.2. Nutritional status
Body weight was measured using an electronic scale
(Tanita Corporation Arlington Heights, Illinois) and stand-
ing height using a wall stadiometer. Thereafter, body mass
index (BMI; kg/m2) was calculated. Biological evaluation
of nutritional status included measurements of serumalbumin as well as vitamin A and E using HPLC-RC
reverse phase C 18.
2.3. CF status
Pulmonary function was measured using FEV1 (L/s) and
% of FEV1 predicted (Medgraphic 1870, St-Paul Minne-
sota). Genotype status was extracted from medical files.
Pancreatic insufficiency was defined by current enzyme
supplementation.
2.4. Fasting biochemical dosages
Inflammatory profile included complete blood count,
plasma fibrinogen and C-reactive protein concentrations
done in duplicates (Nephelometer, Beckman Cloutier
Canada Inc). Glycated Haemoglobin (Immunoturbidimeter,
ADVIA1650, Bayer health care diagnostics/Toronto,
Ontario, Canada) was used as an index of blood glucose
control in the previous months.
2.5. Oral Glucose Tolerance Test (OGTT)
All subjects underwent a 2-hours OGTT. After an
overnight fast, subjects ingested in less than 5 min a
glucose solution: 1.75 g/kg of body weight with a maximum
of 75 g according to the guidelines of the American
Diabetes Association [7]. Blood samples were taken at 0,
30, 60, 90 and 120 min to measure plasma glucose and
insulin concentrations. Plasma glucose level was determined
immediately in duplicate with a Glucose Analyzer (Beck-
man, Fullerton California USA) [5]. Insulin concentration
was determined in duplicate using human specific insulin
RIA (Linco Research, Inc. St-Charles MO USA). All new
cases of CFRD were confirmed by a second OGTT within
2 months.
2.6. Insulin secretion and insulin sensitivity assessment
We used insulin and glucose values during the OGTT to
evaluate insulin secretion and sensitivity. From the various
published indices we chose a priori Stumvoll's indices
because, to our knowledge, it's the only ones has been
validated both for evaluation of insulin sensitivity1 and
insulin secretion (early insulin release2 and late insulin
release3) against golden standard methods: euglycemic
hyperinsulinemic and intravenous glucose tolerance test [8]
in various populations [9].
Table 1
Physical and biochemical characteristics of CF patients and control subjects
Controls CF patients
NGT IGT CFRD
Prevalence – 60% 28% 12%
Sex M/F (n) 8/6 37/28 15/16 7/6
Age (years) 24.5±3.8 27.2±7.8 27.9±8.3 28.5±8.0
Weight (kg) 67.7±9.6 60.2±10.3 60.7±11.6 59.2±12.1
BMI (kg/m2) 22.7±1.6 21.6±2.9 21.5±3.5 22.1±3.7
Pancreatic enzyme Δ 0.00% 80.00% 83.87% 100.00%
FEV1 (L/s) – 2.57±0.79 2.64±0.92 1.88±0.76
% FEV1 – 72.06±20.97 76.14±22.33 54.62±17.95
ΔF508 homozygousΔ – 48% 43.5% 80%
ΔF508 heterozygousΔ – 40% 43.5% 20%
Other genotype/unknownΔ – 12% 13% 0%
CRP (mg/L) 1.88±0.82 5.50±5.23⁎ 5.68±6.25 8.79±8.19⁎
Fibrinogen (g/L) 2.42±0.50 3.03±0.63⁎ 3.03±0.61⁎ 3.17±0.58⁎
⁎: P<0.05 versus Controls.
Δ: % patients.
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The data are expressed as the mean±SD. A one-way
ANOVAwas performed to analyze mean differences among
the groups. When significant differences were found, a
Dunnett post-hoc test was performed to identify group
differences. Significance was accepted at P<0.05.
3. Results
Five patients were excluded because of suspected
infection and/or unconfirmed diabetes on the second
OGTT and/or fasting hyperglycemia. Therefore, the results
are derived from 109 patients. According to conventional
criteria, patients were classified in 3 groups: normal
glucose tolerance (NGT), impaired glucose tolerance
(IGT) and diabetic (CFRD) [3,5]. All control subjects
had NGT. In the CF population, glucose tolerance
abnormalities affected 40% of the screened subjects with
28% having IGT and 12% new CFRD (Table 1). Although
in the normal range value, CF patients without diabetes
had a slightly higher but significant fasting plasma glucoseTable 2
Parameters of glucose homeostasis in CF patients and controls subjects
Controls CF
NGT
Fasting plasma glucose (mmol/L) 5.0±0.6
HbA1c 0.049±0.003 0
2 h post-OGTT plasma glucose (mmol/L) 4.7±1.1
2 h Glucose AUC 677.0±136.5 9
2 h Insulin AUC 6496.93±2818.87 524
Early insulin secretion index 1466.76±541.70 64
Late insulin secretion index 374.25±121.00 14
Insulin sensitivity index 0.093±0.020 0
⁎: P<0.05 versus Controls, ⁎⁎: P<0.0001 versus Controls, †: P<0.05 versu
#: P<0.0001 versus CF-IGT.compared to control subjects (Table 2). As previously
reported, CFRD status is associated both with a high
prevalence of ΔF508 mutation and a constant requirement
for pancreatic enzyme supplementation (Table 1) [10,11].
CF was associated with systemic inflammation as shown
by the significantly higher concentration of fibrinogen
compared to the control group. A trend for higher CRP
levels was observed in the diabetes group. Weight, BMI,
sex ratio (Table 1) and biochemical markers for the
nutritional status (data not shown) revealed no significant
differences between the groups.
Within normal range, both CF-NGT and IGT showed a
significantly higher HbA1c (0.5%) compared to control
subjects. Subjects with CFRD had a further higher HbA1c
(0.6%) compared to CF-IGT (Table 2). Within normal range,
fasting and 2-hours plasma glucose levels in CF subjects
with NGT presented a significantly higher glucose excursion
at 60 and 90 min compared to the control subjects (Fig. 1).
This was confirmed by a glucose area under the curve (AUC)
higher of 41% compared with control subjects (Table 2). The











s CF-NGT, ∇: P<0.0001 versus CF-NGT, ‡: P<0.05 versus CF-IGT,
Fig. 3. Disposition index: Values for early insulin secretion index are
adjusted for insulin sensitivity index ♦: Control subjects; : CF normal
glucose tolerance patients (CF-NGT); ▪: CF impaired glucose tolerance
patients (CF-IGT); ▴: Cystic fibrosis related diabetes CFRD).
Fig. 1. Plasma glucose values following a 1.75 g/kg 2 h-OGTT-♦-: Control
subjects; : CF normal glucose tolerance patients (CF-NGT); :
CF impaired glucose tolerance patients (CF-IGT); -▴-: Cystic fibrosis
related diabetes (CFRD) ⁎: P<0.05 versus Controls †: P<0.05 versus CF-
NGT ‡: P<0.05 versus CF-IGT.
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during the OGTT between CF patients groups as well as
between CF patients and controls subjects (Table 2).
However, insulin secretion is a dynamic process in which
early insulin secretion plays a major role to control post-
prandial glucose excursion [6,12,13]. When insulin secre-
tion was analyzed with the Stumvoll indices as early and
late insulin secretion [14], it is obvious that CF status was
characterized by a major early insulin secretion defect with
a further deterioration between CF-NGT and CFRD
patients (Fig. 2 and Table 2). The insulin sensitivity
index [15] was similar in the control subjects and CF
patients with NGT but was significantly lower in those
with IGT and CFRD (Table 2).
We also determined the disposition index, which reflects
the ability of beta cells to compensate for insulin resistance
[16]. As shown in Fig. 3, CF was associated with a major
defect in early insulin secretion. Furthermore, reduced
insulin sensitivity also contributed to glucose intolerance in
CF patients. Indeed, between CF-NGT and CFRD both earlyFig. 2. Plasma insulin values following a 1.75 g/kg 2 h-OGTT -♦-: Control
subjects; : CF normal glucose tolerance patients (CF-NGT);
: CF impaired glucose tolerance patients (CF-IGT); -▴-: Cystic
fibrosis related diabetes (CFRD) ⁎: P<0.05 versus Controls †: P<0.05
versus CF-NGT.insulin secretion and insulin sensitivity were reduced by
approximately 50% compared to controls subjects (Fig. 3
and Table 2).
Based on the glucose tolerance categories, using the
conventional criteria, there was no difference in clinical
parameters (pulmonary function, weight, etc.) between CF
patients groups as well as between CF patients and controls
subjects (Table 1). However, it was postulated that the higher
glucose AUC, early insulin secretion defect and insulin
resistance observed in the CF population, could be better
associated to clinical status than the conventional glucose
tolerance classification based on OGTT. To test this
hypothesis, the CF population was divided into quartiles
based either on glucose AUC, early insulin secretion or
insulin sensitivity indices. The higher glucose AUC quartile
was associated with lower FEV1 (−18.2%; P<0.05), a
higher fibrinogen level (P<0.05) and a tendency for higher
CRP (Table 3). While the lower insulin secretion quartile
was associated with a significant FEV1 reduction (−15.3%;
P<0.05) (Table 3). On the other hand, when CF subjects
were divided into quartiles based on their insulin sensitivity
index, there was no difference in pulmonary function be-
tween the fist and the fourth quartiles even if the latter had
a higher CRP levels (Table 3). In all cases, significant
difference was only reached for the comparison between
extreme quartiles.
The breakout into quartiles demonstrated that the first
quartile with the lower glucose AUC and the higher insulin
sensitivity identify CF patients with NGT (100 and 96%
respectively). On the other hand, the fourth quartile with the
highest glucose AUC and the lowest insulin sensitivity
identified mostly CF patients with glucose intolerance (IGT
or CFRD; 86 and 92% respectively). However, 43% of
patients included in the highest quartile of glucose AUC
were not identified as CFRD patients, indicating that CF
patients can have a large glucose excursion with a normal
fasting and 2-hours plasma glucose (Table 3). The breakout
Table 3
Differences between 1st and 4th quartiles for glucose AUC, early insulin secretion and insulin sensitivity indices
2 h glucose AUC Early insulin secretion index Insulin sensitivity index
Q1 Q4 Q1 Q4 Q1 Q4
823.38 1464.11 990.16 142.39 0.106 0.047
Prevalence (%) NGT/IGT/CFRD 100/0/0 14/29/57 74/22/4 38.5/19/42.5 96/4/0 8/38/54
Weight (kg) 58.4 61.3 63.3 58.7 60.1 61.0
FEV1 (%) 77.25 59.04⁎ 78.12 62.85⁎ 71.92 66.33
CRP (mg/L) 4.15 7.96 6.82 7.23 3.78 8.60⁎
Fibrinogen (g/L) 2.8 3.3⁎ 3.1 3.2 2.9 3.2
Genotype (%) 1/2/3∇ 56/33/1 64/29/7 38/50/12 62/35/3 58/31/11 69/31/0
⁎ : P<0.05 versus Q1.
∇: 1=Homogygous for ΔF508 mutation.
2=Heterozygous for ΔF508 mutation.
3=Other genotype/unknown.
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natory, with 38.5% of CF-NGT patients in the lowest
quartile, due to the fact that in CF patients, early insulin
secretion was already blunted (Table 3).
4. Discussion
This is a cross-sectional observational study on all eligible
patients not known to be diabetic attending the CF clinic
over an 18-months period. Our results demonstrate numer-
ous new findings potentially relevant for clinical practice.
We confirm that the adult CF population is at very high risk
for glucose intolerance and diabetes [17]. The study also
shows that CF patients with normal glucose tolerance have
an abnormally high glucose excursion in response to 75 g
glucose challenge (Fig. 1 and Table 2). This could be due to
the major defect in early insulin secretion observed in CF
patients. Furthermore, this higher concentration in post-load
plasma glucose is significantly associated with worse
pulmonary function (Table 3). This suggests that abnormally
high glucose excursion stimulates inflammation, which
could be involved in the progression of glucose intolerance,
and the deterioration of pulmonary function (Table 3).
Overall, 40% of the CF patients tested had an abnormal
glucose tolerance; of these, 31 (70%) had IGT and 13 (30%)
had diabetes. These values underestimate the true prevalence
since known diabetic and infected patients were not tested
but are consistent with published data [18]. Such high
prevalence of abnormal glucose tolerance in this CF
population overemphasizes the importance of screening for
glucose intolerance [5] using the OGTT since most patients
had fasting plasma glucose below 6.1 mmol/L [19–21]. The
use of the OGTT is further justified by the observation that
even the patients with normal glucose tolerance already
showed an abnormally high glucose excursion in response to
the 75 g glucose challenge (Fig. 1 and Table 2). This would
be totally missed if we had used only the 2-hours time points
as recommended. By including the 30, 60 and 90 min time
points, we were able to calculate glucose AUC. In CF-NGT
patients with a mean 2-hours plasma glucose of 5.8±1.1 mmol/L, the glucose AUC was 954.3 compared to 677.0
in the control group, a 41% increase (P<0.0001).
Abnormality in glucose homeostasis was also suggested by
higher fasting plasma glucose compared to control subjects
(5.3±0.5 versus 5.0±0.6; P<0.05) and higher HbA1c
(0.056±0.004 versus 0.049±0.003; P<0.05). (Table 2).
These observations strongly suggest that the current defi-
nition of diabetes based on the 2-hours plasma glucose post
75 g glucose may not be the most accurate method for early
detection of glucose tolerance abnormalities in CF. This has
already been recently suggested by Dobson et al. [22] using
continuous glucose monitoring. Results of that study suggest
that abnormal glucose homeostasis is an early feature of CF.
In line with these findings, we propose that in CF patients,
screening of glucose intolerance should be performed using
5 time points during an OGTT. This recommendation could
have an impact on prognosis and treatment if further research
demonstrate that an earlier treatment is associated with a
better clinical outcome (i.e. better preservation of pulmonary
function). However this will have to be balanced against
increased complexity and higher costs.
The most likely explanation for this excessive glucose
excursion appears to be a major early insulin secretion defect
already present in the CF-NGT group compared to control
subjects (Fig. 2 and Table 2). This observation confirms
earlier reports in smaller groups of CF patients using either
the intravenous glucose tolerance test (IVGTT) or the hyper-
glycemic clamp [13,23]. However, most of the previous
publications in this field did not include a control group.
It is well established that beta cells defect is involved in
the development of CFRD, however, the role of insulin re-
sistance remains controversial. In fact, a number of studies
using different methodologies have measured insulin sensi-
tivity in patients with CF and have reported it to be either
normal [24,25], reduced [23,26–29] or increased [30,31]. In
the present study, there was a significant reduction in insulin
sensitivity in the CF patients with IGT and diabetes, but not in
subjects with NGT compared to control individuals (Fig. 3
and Table 2). To better understand the role of insulin resistance
in the deterioration of glucose tolerance in patients with CF,
381M. Costa et al. / Journal of Cystic Fibrosis 6 (2007) 376–383we plotted insulin sensitivity against early insulin secretion in
Fig. 3. To maintain normal glucose tolerance there is a well
described hyperbolic sensitivity-secretion relationship [16].
That is, a reduction in insulin sensitivity is associated with an
increase insulin secretion.
The disposition index is a graphical representation of this
concept to evaluate the ability of the beta-cells to respond
adequately to any degree of insulin resistance. This study
demonstrates that while patients with NGT have a similar
insulin sensitivity than the control group, their early insulin
secretion is lower (P<0.05) (Table 2 and Fig. 3). In patients
with IGT, however, there was a reduction in insulin
sensitivity (P<0.05 compared to Controls and CF-NGT),
in the absence of any additional change in the early insulin
secretion (Table 2 and Fig. 3). Finally, in patients with
CFRD, there is a further reduction in both insulin sensitivity
(P<0.05), insulin secretion (P<0.05) (Table 2 and Fig. 3).
It can therefore be proposed that the first defect initiating
deterioration in glucose homeostasis is a reduction in the
early insulin secretion. This lower early insulin release will
result in abnormally high glucose excursion despite a normal
OGTT based on the 2-hours time points. The abnormally
elevated glucose excursion could induce glucose toxicity
[32] resulting in a reduction in insulin sensitivity and later a
further impairment of insulin secretion leading to diabetes. In
this paradigm, both insulin secretion defect and reduced
insulin sensitivity contribute to glucose intolerance.
Based on the standard OGTT using the 2-hours time
points, despite a trend, there was no significant difference in
pulmonary function between the patients with NGT, those
with IGT and newly diagnosed CFRD (Table 1). These ob-
servations are somewhat different than those in the literature
where diabetes was predictive of a worse pulmonary function
degradation and an increased mortality rate [33]. It was also
shown that the treatment of diabetes in these patients was
associated with an improvement in the clinical status [34–
36]. It is possible that this strong association is due to the fact
that these studies included long standing CFRD, frequently
presenting confounding factors such as malnutrition and
infection [17,33,37,38]. In the present study, only those
patients who were not known to be diabetic were included.
Therefore, the lack of association between the three glucose
tolerance categories and pulmonary function could be due to
the small number of patients with newCFRD (n=13) or to the
fact that other parameters are more relevant at these earlier
stage of the disease. Data for pulmonary function in the
previous years were unfortunately only available for a sub-
fraction of the cohort. For this reason, we could not evaluate
if CFRD patients have a more pronounced decline of pul-
monary function than other categories of subjects during
years preceding the diagnosis.
When the glucose excursion and the early insulin
secretion were divided in quartiles, significant differences
could be found between extreme quartiles. The quartile with
the highest glucose excursion and the lower insulin secretion
were significantly associated with a worse pulmonary func-tion (Table 3). On the other hand, there was no relationship
between insulin sensitivity and pulmonary function. The
significant relationship between glucose excursion and
decreased FEV1 could imply that glucose toxicity plays a
major role in the deterioration of both glucose tolerance and
pulmonary function. It is tempting to propose that glucose
excursion stimulates sub-clinical inflammation, which could
accelerate the deterioration in glucose tolerance and pulmo-
nary function. In fact, both in type 1 and type 2 diabetes, a
negative correlation has already been reported between a
higher HbA1c and more rapid FEV1 deterioration [1]. Ele-
vated glucose could affect lung function through various
mechanisms such as promotion of bacterial growth, impair-
ing host immune function and/or up-regulating the inflam-
matory response to pulmonary infection [39]. Finally, in the
later stages, when insulin secretion defect reach a certain
threshold, this could contribute to protein wasting [40–42]
and thus to weight reduction described in long standing
CFRD [17,33,37,38].
The relationship between genotype and CFRD is
controversial. In the present study we report that subjects
homozygous forΔF508 mutation are over-represented in the
CFRD category (Table 1) which have already been reported
by some investigators [10,11,20] but not by others [43,44]
This relationship might be related to a more severe early
insulin secretion defect since subjects homozygous for
ΔF508 mutation are also over-represented in the quartile
with the lower insulin secretion (Table 3).
Our study has limitations: a cross-sectional design, which
precludes from definitive conclusion about causal and effect
relationships. Insulin secretion and sensitivity were not di-
rectly measured from intravenous glucose tolerance test or
hyperglycaemic clamp and euglycemic hyperinsulinemic
clamp, but were evaluated from OGTT using validated
indices [14,15]. On the other hand, the OGTT allows us to
evaluate in the same test four parameters: glucose tolerance
status, glucose AUC as well as insulin sensitivity and se-
cretion. The fact that we excluded known diabetics from the
present work preclude the calculation of the true prevalence
of glucose tolerance abnormalities but was important to
avoid confounding factors to investigate the interrelationship
between glucose tolerance abnormalities and clinical status.
Finally, for the analysis based on quartiles, the significant
level was reached only for the comparison between the first
and the fourth quartiles. The absence of statistical dose–
response effect increases the risk that confounding factors
explain this relationship or that there is a threshold beyond
which the relationship does not exist.
The present study confirms the high prevalence of ab-
normal glucose tolerance in patients with CF. Even subjects
with normal glucose tolerance already have a high glucose
excursion and a blunted early insulin secretion in response
to an OGTT. Furthermore, this higher glucose excursion is
significantly associated with worse pulmonary function. We
propose that this could be due to sub-clinical inflammation
triggered by repeated glucose excursion. These and other
382 M. Costa et al. / Journal of Cystic Fibrosis 6 (2007) 376–383observations support the current recommendations for yearly
OGTT-screening of the CF population without fasting hyper-
glycaemia. The present study, however, would suggest that
a 5 time points OGTT should be performed and that the
diagnostic criteria might be revised. This strategy might
improve our ability to detect high risk patients and under-
stand the underlying pathophysiology involved in the devel-
opment of glucose intolerance. The early association of
glucose tolerance abnormalities with a worse clinical status
suggests that there is a therapeutic window to prevent CFRD
as well as clinical deterioration associated with its occur-
rence. However, this should be confirmed in prospective
observational cohorts and early intervention trials.
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